Services on Demand
Journal
Article
English (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO
Related links
Similars in
SciELO
Share
Permalink
Revista argentina de reumatología
Print version ISSN 0327-4411On-line version ISSN 2362-3675
Abstract
LINS ALENCAR, Bianca; BUSATO, Valentina; NISIHARA, Renato and LAROCCA SKARE, Thelma. Seguridad de la vacunación COVID-19 en una muestra de pacientes brasileños con lupus eritematoso sistémico. Rev. argent. reumatolg. [online]. 2024, vol.35, n.1, pp.11-16. ISSN 0327-4411. http://dx.doi.org/10.47196/rar.v35i1.791.
Objectives:
to study the side effects and the risk of disease flare after COVID-19 vaccination in Brazilian patients with Systemic Lupus erythematosus (SLE).
Materials and methods:
this retrospective study investigated a sample of 101 SLE patients for disease activity through the SLE disease activity index (SLEDAI) prior to and after two vaccine doses against SARS-COv-2. Side effects after vaccination were recorded.
Results:
in this sample, patients receiving two doses of the same vaccine were 10.3% for CoronaVAc; 42.2% for Pfizer, and 47.3% for Astra-Zeneca. Side effects were detected in 76.2% of them, and most of them were mild and moderate; the most common were local pain (62.3%), headache (36.6%), and fatigue (34.6%). The SLEDAI prior to the first dose and after the second dose did not change significantly (p=0.68). Only 4.1% of individuals had increased in SLEDAI ≥than 3 points.
Conclusions:
vaccination against COVID-19 was well tolerated and safe in SLE patients.
Keywords : systemic lupus erythematosus; COVID-19; vaccines; safety.
